{"id":44348,"date":"2025-10-25T00:05:05","date_gmt":"2025-10-24T16:05:05","guid":{"rendered":"https:\/\/flcube.com\/?p=44348"},"modified":"2025-10-25T00:05:06","modified_gmt":"2025-10-24T16:05:06","slug":"eli-lilly-partners-with-cipla-to-distribute-new-tirzepatide-brand-yurpeak-in-india","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=44348","title":{"rendered":"Eli\u202fLilly Partners with Cipla to Distribute New Tirzepatide Brand \u201cYurpeak\u201d in India"},"content":{"rendered":"\n<p>Eli Lilly and Company\u202f(India) Pvt.\u202fLtd. (Lilly) and Cipla Limited (<a href=\"https:\/\/www.google.com\/finance\/quote\/500087:BOM\">BOM: 500087<\/a>,\u00a0<a href=\"https:\/\/www.google.com\/finance\/quote\/CIPLA:NSE\">NSE: CIPLA<\/a>) today announced a strategic distribution agreement for Lilly\u2019s second tirzepatide product, <strong>Yurpeak<\/strong>, in India. The deal expands market access beyond the limited geographic footprint where Lilly has already launched its flagship tirzepatide, <strong>Mounjaro<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-terms-of-the-agreement\"><strong>Key Terms of the Agreement<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Distribution Rights<\/strong> \u2013 Cipla will obtain exclusive rights to distribute and promote Yurpeak across India.<\/li>\n\n\n\n<li><strong>Manufacturing &amp; Supply<\/strong> \u2013 Lilly will manufacture and supply the product to Cipla under the same pricing structure as Mounjaro.<\/li>\n\n\n\n<li><strong>Commercial Scope<\/strong> \u2013 The partnership aims to broaden availability of tirzepatide nationwide, reaching patients outside major urban centers.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-yurpeak\"><strong>Product Profile \u2013 Yurpeak<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Active Ingredient<\/strong> \u2013 Tirzepatide, a dual agonist of GIP and GLP\u20111 receptors.<\/li>\n\n\n\n<li><strong>Indications<\/strong> \u2013 Adjunct to diet and exercise for type\u202f2 diabetes; chronic weight management in adults with BMI\u202f\u2265\u202f27 (overweight) or\u202f\u2265\u202f30 (obese) plus at least one weight\u2011related comorbidity.<\/li>\n\n\n\n<li><strong>Formulation<\/strong> \u2013 KwikPen pre\u2011filled pen, multi\u2011dose single\u2011patient use, 4 fixed doses per pen.<\/li>\n\n\n\n<li><strong>Dosing<\/strong> \u2013 Once weekly, six strength options: 2.5\u202fmg, 5\u202fmg, 7.5\u202fmg, 10\u202fmg, 12.5\u202fmg, or 15\u202fmg.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-impact\"><strong>Strategic Impact<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Expanded Reach<\/strong> \u2013 Cipla\u2019s extensive distribution network will enable Yurpeak to reach underserved regions, enhancing treatment access for diabetes and obesity patients.<\/li>\n\n\n\n<li><strong>Competitive Positioning<\/strong> \u2013 By offering a second tirzepatide product at the same price point, Lilly reinforces its leadership in the emerging dual\u2011agonist market.<\/li>\n\n\n\n<li><strong>Collaborative Synergy<\/strong> \u2013 The partnership leverages Lilly\u2019s clinical expertise and Cipla\u2019s local market knowledge, promising a streamlined go\u2011to\u2011market strategy.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h3>\n\n\n\n<p>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly and Company\u202f(India) Pvt.\u202fLtd. (Lilly) and Cipla Limited (BOM: 500087,\u00a0NSE: CIPLA) today announced a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":44350,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[3866,1834,199,1835,86],"class_list":["post-44348","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-bom-500087","tag-cipla","tag-eli-lilly","tag-nse-cipla","tag-obesity"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eli\u202fLilly Partners with Cipla to Distribute New Tirzepatide Brand \u201cYurpeak\u201d in India - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly and Company\u202f(India) Pvt.\u202fLtd. (Lilly) and Cipla Limited (BOM: 500087,\u00a0NSE: CIPLA) today announced a strategic distribution agreement for Lilly\u2019s second tirzepatide product, Yurpeak, in India. The deal expands market access beyond the limited geographic footprint where Lilly has already launched its flagship tirzepatide, Mounjaro.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=44348\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli\u202fLilly Partners with Cipla to Distribute New Tirzepatide Brand \u201cYurpeak\u201d in India\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly and Company\u202f(India) Pvt.\u202fLtd. (Lilly) and Cipla Limited (BOM: 500087,\u00a0NSE: CIPLA) today announced a strategic distribution agreement for Lilly\u2019s second tirzepatide product, Yurpeak, in India. The deal expands market access beyond the limited geographic footprint where Lilly has already launched its flagship tirzepatide, Mounjaro.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=44348\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-24T16:05:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-24T16:05:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2414.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44348#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44348\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli\u202fLilly Partners with Cipla to Distribute New Tirzepatide Brand \u201cYurpeak\u201d in India\",\"datePublished\":\"2025-10-24T16:05:05+00:00\",\"dateModified\":\"2025-10-24T16:05:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44348\"},\"wordCount\":275,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44348#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2414.webp\",\"keywords\":[\"BOM: 500087\",\"Cipla\",\"Eli Lilly\",\"NSE: CIPLA\",\"Obesity\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44348#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44348\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=44348\",\"name\":\"Eli\u202fLilly Partners with Cipla to Distribute New Tirzepatide Brand \u201cYurpeak\u201d in India - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44348#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44348#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2414.webp\",\"datePublished\":\"2025-10-24T16:05:05+00:00\",\"dateModified\":\"2025-10-24T16:05:06+00:00\",\"description\":\"Eli Lilly and Company\u202f(India) Pvt.\u202fLtd. (Lilly) and Cipla Limited (BOM: 500087,\u00a0NSE: CIPLA) today announced a strategic distribution agreement for Lilly\u2019s second tirzepatide product, Yurpeak, in India. The deal expands market access beyond the limited geographic footprint where Lilly has already launched its flagship tirzepatide, Mounjaro.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44348#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44348\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44348#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2414.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2414.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eli\u202fLilly Partners with Cipla to Distribute New Tirzepatide Brand \u201cYurpeak\u201d in India\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44348#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli\u202fLilly Partners with Cipla to Distribute New Tirzepatide Brand \u201cYurpeak\u201d in India\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli\u202fLilly Partners with Cipla to Distribute New Tirzepatide Brand \u201cYurpeak\u201d in India - Insight, China&#039;s Pharmaceutical Industry","description":"Eli Lilly and Company\u202f(India) Pvt.\u202fLtd. (Lilly) and Cipla Limited (BOM: 500087,\u00a0NSE: CIPLA) today announced a strategic distribution agreement for Lilly\u2019s second tirzepatide product, Yurpeak, in India. The deal expands market access beyond the limited geographic footprint where Lilly has already launched its flagship tirzepatide, Mounjaro.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=44348","og_locale":"en_US","og_type":"article","og_title":"Eli\u202fLilly Partners with Cipla to Distribute New Tirzepatide Brand \u201cYurpeak\u201d in India","og_description":"Eli Lilly and Company\u202f(India) Pvt.\u202fLtd. (Lilly) and Cipla Limited (BOM: 500087,\u00a0NSE: CIPLA) today announced a strategic distribution agreement for Lilly\u2019s second tirzepatide product, Yurpeak, in India. The deal expands market access beyond the limited geographic footprint where Lilly has already launched its flagship tirzepatide, Mounjaro.","og_url":"https:\/\/flcube.com\/?p=44348","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-24T16:05:05+00:00","article_modified_time":"2025-10-24T16:05:06+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2414.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=44348#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=44348"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli\u202fLilly Partners with Cipla to Distribute New Tirzepatide Brand \u201cYurpeak\u201d in India","datePublished":"2025-10-24T16:05:05+00:00","dateModified":"2025-10-24T16:05:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=44348"},"wordCount":275,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=44348#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2414.webp","keywords":["BOM: 500087","Cipla","Eli Lilly","NSE: CIPLA","Obesity"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=44348#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=44348","url":"https:\/\/flcube.com\/?p=44348","name":"Eli\u202fLilly Partners with Cipla to Distribute New Tirzepatide Brand \u201cYurpeak\u201d in India - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=44348#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=44348#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2414.webp","datePublished":"2025-10-24T16:05:05+00:00","dateModified":"2025-10-24T16:05:06+00:00","description":"Eli Lilly and Company\u202f(India) Pvt.\u202fLtd. (Lilly) and Cipla Limited (BOM: 500087,\u00a0NSE: CIPLA) today announced a strategic distribution agreement for Lilly\u2019s second tirzepatide product, Yurpeak, in India. The deal expands market access beyond the limited geographic footprint where Lilly has already launched its flagship tirzepatide, Mounjaro.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=44348#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=44348"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=44348#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2414.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2414.webp","width":1080,"height":608,"caption":"Eli\u202fLilly Partners with Cipla to Distribute New Tirzepatide Brand \u201cYurpeak\u201d in India"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=44348#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli\u202fLilly Partners with Cipla to Distribute New Tirzepatide Brand \u201cYurpeak\u201d in India"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2414.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44348","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=44348"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44348\/revisions"}],"predecessor-version":[{"id":44351,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44348\/revisions\/44351"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/44350"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=44348"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=44348"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=44348"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}